In the gene delivery technologies market, gene therapy maintained its lead in 2023, supported by therapies like Luxturna and Kymriah. The segment benefits from NIH funding and advances in genetic engineering. Cell therapy, driven by rising adoption in oncology and rare diseases, is showing the fastest growth trajectory. Emergen Research has recently published a detailed report on the global...